Publicaciones (84) Publicaciones de MI KWON KIM

2024

  1. Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients

    Transplantation and Cellular Therapy, Vol. 30, Núm. 3, pp. 306.e1-306.e12

  2. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 205-217

2023

  1. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis

    Leukemia, Vol. 37, Núm. 7, pp. 1511-1520

  2. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

    Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437

  3. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

    Haematologica, Vol. 108, Núm. 1, pp. 110-121

  4. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  5. Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma

    Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 472.e1-472.e4

  6. Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (Journal of Hematology & Oncology, (2023), 16, 1, (58), 10.1186/s13045-023-01450-4)

    Journal of Hematology and Oncology

  7. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  8. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study

    Transplantation and Cellular Therapy, Vol. 29, Núm. 12, pp. 747.e1-747.e10

  9. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

    Journal of Hematology and Oncology, Vol. 16, Núm. 1

  10. Novel Candidate loci and Pathogenic Germline Variants Involved in Familial Hematological Malignancies Revealed by Whole-Exome Sequencing

    Cancers, Vol. 15, Núm. 3

  11. Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide

    Annals of Hematology, Vol. 102, Núm. 6, pp. 1561-1567

  12. Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation

    European Journal of Haematology, Vol. 110, Núm. 6, pp. 659-668

  13. Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy

    Frontiers in immunology, Vol. 14, pp. 1165759

  14. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679

  15. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

    Bone Marrow Transplantation, Vol. 58, Núm. 8, pp. 907-915